Investment Thesis

.

Competitive Moat

DexCom possesses significant intangible assets, including proprietary technology and a strong brand reputation among both patients and healthcare providers, which create substantial switching costs. The company's established relationships with key stakeholders in the diabetes management ecosystem further enhance its competitive position. Over the next 5-10 years, DXCM’s moat appears durable, particularly as it continues to innovate with products like the upcoming Dexcom G7. However, competitive threats from newer entrants and established players like Abbott Laboratories (FreeStyle Libre) could challenge its market share, necessitating vigilant product differentiation and marketing efforts.

Growth Engine

Future revenue growth for DexCom is driven primarily by the expanding total addressable market (TAM) in diabetes management, which is projected to grow as the prevalence of diabetes increases globally. The company benefits from strong pricing power due to its advanced technology and patient-centric solutions, which improve health outcomes. Geographic expansion, particularly into international markets, coupled with new product launches such as the Dexcom G7, will further enhance organic growth. Currently, DexCom is gaining market share, thanks to its reputation for accuracy and reliability, which distinguishes it from competitors.